These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27653914)

  • 1. Effect of the 2013 AHA/ASA guidelines on TPA use in acute ischemic stroke at Assaf Harofeh Medical Center in Israel.
    Kimiagar I; Kalmanovich-Avnery S; Gonen OM; Sacagiu Z; Shevtzov E; Levite R; Weinstein J; Bartal A; Aroesty R; Bhonkar S; Tal S; Leonov Y; Blatt A; Haitov Z; Bar-Hayim S; Armon C
    J Neurol Sci; 2016 Oct; 369():306-309. PubMed ID: 27653914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of tissue plasminogen activator eligibility by sex in the Greater Cincinnati/Northern Kentucky Stroke Study.
    Madsen TE; Khoury JC; Alwell KA; Moomaw CJ; Kissela BM; De Los Rios La Rosa F; Woo D; Adeoye O; Flaherty ML; Khatri P; Ferioli S; Kleindorfer D
    Stroke; 2015 Mar; 46(3):717-21. PubMed ID: 25628307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.
    Heuschmann PU; Berger K; Misselwitz B; Hermanek P; Leffmann C; Adelmann M; Buecker-Nott HJ; Rother J; Neundoerfer B; Kolominsky-Rabas PL; ;
    Stroke; 2003 May; 34(5):1106-13. PubMed ID: 12663875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.
    Charipar R; Charipar E
    WMJ; 2008 Jul; 107(4):176-80. PubMed ID: 18702433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.
    Graham GD
    Stroke; 2003 Dec; 34(12):2847-50. PubMed ID: 14605319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke.
    Cronin CA; Sheth KN; Zhao X; Messé SR; Olson DM; Hernandez AF; Bhatt DL; Schwamm LH; Smith EE
    Stroke; 2014 Sep; 45(9):2745-9. PubMed ID: 25104846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience.
    Salam KA; Ummer K; Pradeep Kumar VG; Noone ML
    Int J Stroke; 2014 Jun; 9(4):426-8. PubMed ID: 23981667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of intravenous thrombolysis for acute ischemic stroke in Asia.
    Sharma VK; Ng KW; Venketasubramanian N; Saqqur M; Teoh HL; Kaul S; Srivastava PM; Sergentanis T; Suwanwela N; Nguyen TH; Lawrence Wong KS; Chan BP
    Int J Stroke; 2011 Dec; 6(6):523-30. PubMed ID: 22111797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.
    LaMonte MP; Bahouth MN; Magder LS; Alcorta RL; Bass RR; Browne BJ; Floccare DJ; Gaasch WR;
    Ann Emerg Med; 2009 Sep; 54(3):319-27. PubMed ID: 19101059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Rate-Limiting Steps in the Provision of Thrombolytics for Acute Ischemic Stroke.
    Metts EL; Bailey AM; Weant KA; Justice SB
    J Pharm Pract; 2017 Dec; 30(6):606-611. PubMed ID: 27834297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
    Eissa A; Krass I; Bajorek BV
    J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute stroke management in the elderly.
    Zeevi N; Chhabra J; Silverman IE; Lee NS; McCullough LD
    Cerebrovasc Dis; 2007; 23(4):304-8. PubMed ID: 17199089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.
    Lubeck DP; Danese MD; Duryea J; Halperin M; Tayama D; Yu E; Lalla D; Grotta JC
    Int J Stroke; 2016 Feb; 11(2):198-205. PubMed ID: 26783311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
    Yamaguchi T; Awano H; Matsuda H; Tanahashi N;
    J Stroke Cerebrovasc Dis; 2017 Apr; 26(4):756-765. PubMed ID: 27887792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.